Trial Profile
A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Anti-digoxin polyclonal antibody (Primary)
- Indications Preeclampsia
- Focus Registrational; Therapeutic Use
- Sponsors AMAG Pharmaceuticals
- 26 Nov 2020 This trial has been suspended in Poland according to European Clinical Trials Database record.
- 09 Oct 2020 This trial has been discontinued in United Kingdom according to European Clinical Trials Database record.
- 02 Sep 2020 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Following a recommendation from the Data and Safety Monitoring Board (DSMB), the study was stopped early for futility. There were no safety concerns raised.